ZobuxaTM (enrofloxacin) Flavored Antibacterial Tablets for Dogs and Cats

国: アメリカ合衆国

言語: 英語

ソース: NLM (National Library of Medicine)

有効成分:

enrofloxacin (UNII: 3DX3XEK1BN) (enrofloxacin - UNII:3DX3XEK1BN)

から入手可能:

Elanco US Inc.

投与経路:

ORAL

処方タイプ:

PRESCRIPTION

適応症:

Zobuxa (enrofloxacin) Flavored Antibacterial Tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. Zobuxa Flavored Antibacterial Tablets are indicated for use in dogs and cats. Enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. Dogs: Based on the studies discussed under the section on Animal Safety Summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. Large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. In clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. However, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant bre

認証ステータス:

Abbreviated New Animal Drug Application

製品の特徴

ZOBUXA- ENROFLOXACIN TABLET
ELANCO US INC.
----------
ZOBUXA
(ENROFLOXACIN) FLAVORED ANTIBACTERIAL TABLETS FOR DOGS AND CATS
CAUTION:
Federal (U.S.A.) law restricts this drug to use by or on the order of
a licensed veterinarian.
Federal law prohibits the extralabel use of this drug in
food-producing animals.
DESCRIPTION:
Enrofloxacin is a synthetic chemotherapeutic agent from the class of
the quinolone carboxylic acid
derivatives. It has antibacterial activity against a broad spectrum of
Gram negative and Gram positive
bacteria (See Tables I and II). It is rapidly absorbed from the
digestive tract, penetrating into all
measured body tissues and fluids (See Table III). Tablets are
available in four tablet sizes (22.7, 68, 136
and 272 mg enrofloxacin).
CHEMICAL NOMENCLATURE AND STRUCTURAL FORMULA:
1-cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic
acid.
ACTIONS:
MICROBIOLOGY: Quinolone carboxylic acid derivatives are classified as
DNA gyrase inhibitors. The
mechanism of action of these compounds is very complex and not yet
fully understood. The site of
action is bacterial gyrase, a synthesis promoting enzyme. The effect
on _Escherichia coli_ is the inhibition
of DNA synthesis through prevention of DNA supercoiling. Among other
things, such compounds lead
to the cessation of cell respiration and division. They may also
interrupt bacterial membrane integrity.
Enrofloxacin is bactericidal, with activity against both Gram negative
and Gram positive bacteria. The
minimum inhibitory concentrations (MICs) were determined for a series
of 39 isolates representing 9
genera of bacteria from
natural infections in dogs and cats, selected principally because of
resistance to one or more of the
following antibiotics: ampicillin, cephalothin, colistin,
chloramphenicol, erythromycin, gentamicin,
kanamycin, penicillin, streptomycin, tetracycline, triple sulfa and
sulfa/trimethoprim. The MIC values for
enrofloxacin against these isolates are presented in Table I. Most
strains of these organisms w